Analysts’ Viewpoint
Incorporation of nanotechnology, sorbent-based techniques, and water-saving strategies is the key trend in the continuous renal replacement therapy (CRRT) ecosystem. Nanotechnology is anticipated to enhance the portability of future devices. Rise in acute kidney injury diseases, increase in patient pool, advancements in technology, surge in geriatric population, growth in investments, and surge in number of dialysis centers are likely to fuel market development.
Technological advances in continuous renal replacement therapies is likely to present significant opportunities for market expansion in the next few years. Constant need for effective follow-up among patients has induced manufacturers to develop innovative artificial intelligence (AI) technology and sensors, which can be used in ICUs to predict which patients are at high risk of imminent deterioration.
CRRT is a preferred modality for managing the hemodynamic status of patients suffering from acute kidney injury. Patients with acute renal failure and those experiencing complications, such as imperfections or multiple organ failure in their circulatory systems that include edema and cardiac insufficiency, are also treated using CRRT systems. Other complications where these systems are used include postoperative liver failure, fulminant hepatitis, serve acute pancreatitis, and multiple organ failure.
The global continuous renal replacement therapy market size is driven by the increase in global geriatric population. This population is more prone to chronic diseases such as chronic kidney disease (CKD). According to the United Nations (UN), the global geriatric population (65 years or above) stood at 703 million in 2019. The number is projected to double to reach 1.5 billion by 2050. According to estimates from researchers at Johns Hopkins University, more than 50% of individuals over the age of 75 are believed to be afflicted with kidney disease. Kidney disease has also been found to be more prevalent in people over the age of 60 compared to the rest of the general population.
According to Centers for Disease Control and Prevention (CDC) estimates, CKD is more common in individuals aged 65 years or older (38%) than in people aged 45–64 years (12%) or 18–44 years (6%). CKD is slightly more common in women (14%) than men (12%). The CDC stated that more than one in seven (15%) of the U.S. adults, or 37 million patients, are estimated to have CKD currently.
Chronic kidney disease has been recognized as a leading public health issue worldwide. The global estimated prevalence of CKD is 13.4% (11.7%–15.1%), and patients with end-stage kidney disease (ESKD) needing renal replacement therapy are estimated between 4.90 million and 7.08 million. The global prevalence of CKD stood at 9.1%, which was about 700 million cases, in 2017. CKD is a major public health issue in low- and middle-income countries (LMICs). Its prevalence has been rapidly increasing in LMICs, particularly in Asia.
Rise in number of dialysis centers is likely to drive the global continuous renal replacement therapy business during the forecast period. Growth in the market can be ascribed to the rise in prevalence of acute kidney injury (AKI), presence of large number of hospitals in the U.S., and well-developed healthcare infrastructure.
Fresenius Medical Care owned and managed around 3,928 dialysis clinics in 2018 as against 3,752 dialysis clinics in 2017. According to American Hospital Association, the U.S had 5,141 community hospitals, 625 nonfederal psychiatric hospitals, and 208 federal government hospitals in 2021.
According to the Centers for Disease Control and Prevention, nearly 786,000 people in the U.S. were living with end-stage renal disease (ESRD) in 2021, with 71% on dialysis and 29% with a kidney transplant. Thus, rise in prevalence of end-stage renal disease has led to an increase in number of dialysis clinics and treatment centers.
Leading players in the industry are undertaking initiatives to reach maximum ESRD patients across all regions by increasing the number of dialysis centers. For instance, B. Braun Melsungen AG alone has more than 300 centers in Europe, Africa, and Asia Pacific. On World Kidney Day on March 9, 2017, Fresenius Medical Care launched a brand new Asia Pacific-wide corporate social responsibility initiative through a series of public awareness events reaching 6,600 children, parents, and caretakers as well as media, key renal health partners, and governments.
In terms of mode, the global market has been classified into slow continuous ultrafiltration (SCUF), continuous venovenous haemofiltration (CVVH), continuous venovenous haemodialysis (CVVHD), and continuous venovenous haemodiafiltration (CVVHDF). The continuous venovenous haemofiltration segment held major share during the forecast period. CVVHD is a short term effective temporary treatment for patients suffering from acute or chronic renal failure.
According to an article published by the American Society of Nephrology in 2019, congestive heart failure, which accounts for around 8.0% of all-cause mortality in patients with CKD stages 4 and 5, is directly linked to fluid overload. This is likely to increase the usage of CVVH treatment.
Based on product, the global continuous renal replacement therapy market has been segregated into dialysate & replacement fluids, disposables, and systems. The disposables segment has been split into bloodline sets, hemofilters, and other disposables.
The disposables segment is likely to witness strong growth in the next few years, owing to high volume sales of disposables and optimal usage of bloodline sets, hemofilters, and tubing in continuous dialysis procedures. The hemofilters sub-segment held the largest share of the disposables segment in 2021. The trend is expected to continue in the near future.
As per continuous renal replacement therapy market trends, Europe is projected to account for a leading share during the forecast period owing to the increase in incidence of acute kidney injury and favorable reimbursement policies in the region. Presence of key players, well-established research & development infrastructure, and strong government funding for CRRT for critically ill patients are likely to be other major business catalysts in the region in the next few years.
The market in Asia Pacific is projected to expand at a rapid pace during the forecast period due to strong economic growth, rise in health care infrastructure, increase in geriatric population, and surge in investments for developing advanced CRRT products. Initiatives by local governments of countries to attain self-sufficiency in manufacturing renal replacement devices are likely to be key market catalysts in Middle East & Africa and Latin America.
This report provides profiles of leading players operating in the global continuous renal replacement therapy market. These include Baxter International, Inc., Nipro Corporation, Fresenius Medical Care AG & Co. KGaA, Asahi Kasei Corporation, B. Braun Melsungen AG, Medica SPA, INFOMED SA, Medtronic, and Toray Medical Company Limited (Toray Industries, Inc.). These players are focused on adopting organic and inorganic growth strategies to strengthen their product portfolio to improve patient healthcare. Companies are focusing on increasing their geographical footprint through mergers & acquisitions and investment in research & development activities in order to remain competitive in the business.
Leading players have been profiled in the market report based on parameters such as company overview, financial overview, strategies, portfolio, segments, and recent developments.
|
Attribute |
Detail |
|
Size in 2021 |
US$ 1.2 Bn |
|
Forecast (Value) in 2031 |
More than US$ 2.5 Bn |
|
Compound Annual Growth Rate (CAGR) |
7.5% |
|
Forecast Period |
2022–2031 |
|
Historical Data Available for |
2017–2021 |
|
Quantitative Units |
US$ Bn for Value |
|
Market Analysis |
It includes segment analysis as well as regional level analysis. Moreover, qualitative analysis includes drivers, restraints, opportunities, key trends, and parent industry overview. |
|
Competition Landscape |
|
|
Format |
Electronic (PDF) + Excel |
|
Segmentation |
|
|
Regions Covered |
|
|
Countries Covered |
|
|
Companies Profiled |
|
|
Customization Scope |
Available upon request |
|
Pricing |
Available upon request |
The industry was valued at US$ 1.2 Bn in 2021
It is projected to reach more than US$ 2.5 Bn by 2031
The market is anticipated to grow at a CAGR of 7.5% from 2022 to 2031
Increase in incidence of acute kidney injury, rapidly aging population with increase in co-morbidities, rise in number of dialysis centers across the world, and shift in government focus toward providing better health care facilities
Baxter International, Inc., Nipro Corporation, Fresenius Medical Care AG & Co. KGaA, Asahi Kasei Corporation, B. Braun Melsungen AG, Medica SPA, INFOMED SA, Medtronic, and Toray Medical Company Limited (Toray Industries, Inc.)
1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Continuous Renal Replacement Therapy Market
4. Market Overview
4.1. Introduction
4.1.1. Market Definition
4.1.2. Industry Evolution / Developments
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Continuous Renal Replacement Therapy Market Analysis and Forecast, 2017–2031
4.4.1. Market Revenue Projections (US$ Mn)
5. Market Outlook
5.1. Incidence of Acute Kidney Injury Across the Globe
5.2. Rise in Prevalence of Diabetes and Hypertension
5.3. Reimbursement Scenario by Region/globally
5.4. Regulatory Scenario by Region/globally
5.5. Recent Technological Developments in Continuous Renal Replacement Therapy
5.6. Development of CRRT System for Pediatric Patients
5.7. Key Mergers & Acquisitions
6. Global Continuous Renal Replacement Therapy Market Analysis and Forecast, by Mode
6.1. Introduction & Definition
6.2. Key Findings / Developments
6.3. Market Value Forecast, by Mode, 2017–2031
6.3.1. Slow Continuous Ultrafiltration (SCUF)
6.3.2. Continuous Venovenous Hemofiltration (CVVHF)
6.3.3. Continuous Venovenous Hemodialysis (CVVHD)
6.3.4. Continuous Venovenous Hemodiafiltration (CVVHDF)
6.4. Market Attractiveness Analysis, by Mode
7. Global Continuous Renal Replacement Therapy Market Analysis and Forecast, by Product
7.1. Introduction & Definition
7.2. Key Findings / Developments
7.3. Market Value Forecast, by Product, 2017–2031
7.3.1. Dialysate & Replacement Fluids
7.3.2. Disposables
7.3.2.1. Bloodline Sets
7.3.2.2. Hemofilters
7.3.2.3. Other Disposables
7.3.3. Systems
7.4. Market Attractiveness Analysis, by Product
8. Global Continuous Renal Replacement Therapy Market Analysis and Forecast, by Therapy
8.1. Introduction & Definition
8.2. Key Findings / Developments
8.3. Market Value Forecast, by Therapy, 2017–2031
8.3.1. Renal
8.3.2. Non-renal
8.3.3. Combination
8.4. Market Attractiveness Analysis, by Therapy
9. Global Continuous Renal Replacement Therapy Market Analysis and Forecast, by End-user
9.1. Introduction & Definition
9.2. Key Findings / Developments
9.3. Market Value Forecast, by End-user, 2017–2031
9.3.1. Hospitals
9.3.2. Clinics
9.3.3. Others
9.4. Market Attractiveness Analysis, by End-user
10. Global Continuous Renal Replacement Therapy Market Analysis and Forecast, by Region
10.1. Key Findings
10.2. Market Value Forecast, by Region
10.2.1. North America
10.2.2. Europe
10.2.3. Asia Pacific
10.2.4. Latin America
10.2.5. Middle East & Africa
10.3. Market Attractiveness Analysis, by Region
11. North America Continuous Renal Replacement Therapy Market Analysis and Forecast
11.1. Introduction
11.1.1. Key Findings
11.2. Market Value Forecast, by Mode, 2017–2031
11.2.1. Slow Continuous Ultrafiltration (SCUF)
11.2.2. Continuous Venovenous Hemofiltration (CVVHF)
11.2.3. Continuous Venovenous Hemodialysis (CVVHD)
11.2.4. Continuous Venovenous Hemodiafiltration (CVVHDF)
11.3. Market Value Forecast, by Product, 2017–2031
11.3.1. Dialysate & Replacement Fluids
11.3.2. Disposables
11.3.2.1. Bloodline Sets
11.3.2.2. Hemofilters
11.3.2.3. Other Disposables
11.3.3. Systems
11.4. Market Value Forecast, by Therapy, 2017–2031
11.4.1. Renal
11.4.2. Non-renal
11.4.3. Combination
11.5. Market Value Forecast, by End-user, 2017–2031
11.5.1. Hospitals
11.5.2. Clinics
11.5.3. Others
11.6. Market Value Forecast, by Country, 2017–2031
11.6.1. U.S.
11.6.2. Canada
11.7. Market Attractiveness Analysis
11.7.1. By Mode
11.7.2. By Product
11.7.3. By Therapy
11.7.4. By End-user
11.7.5. By Country
12. Europe Continuous Renal Replacement Therapy Market Analysis and Forecast
12.1. Introduction
12.1.1. Key Findings
12.2. Market Value Forecast, by Mode, 2017–2031
12.2.1. Slow Continuous Ultrafiltration (SCUF)
12.2.2. Continuous Venovenous Hemofiltration (CVVHF)
12.2.3. Continuous Venovenous Hemodialysis (CVVHD)
12.2.4. Continuous Venovenous Hemodiafiltration (CVVHDF)
12.3. Market Value Forecast, by Product, 2017–2031
12.3.1. Dialysate & Replacement Fluids
12.3.2. Disposables
12.3.2.1. Bloodline Sets
12.3.2.2. Hemofilters
12.3.2.3. Other Disposables
12.3.3. Systems
12.4. Market Value Forecast, by Therapy, 2017–2031
12.4.1. Renal
12.4.2. Non-renal
12.4.3. Combination
12.5. Market Value Forecast, by End-user, 2017–2031
12.5.1. Hospitals
12.5.2. Clinics
12.5.3. Others
12.6. Market Value Forecast, by Country/Sub-region, 2017–2031
12.6.1. Germany
12.6.2. U.K.
12.6.3. France
12.6.4. Spain
12.6.5. Italy
12.6.6. Rest of Europe
12.7. Market Attractiveness Analysis
12.7.1. By Mode
12.7.2. By Product
12.7.3. By Therapy
12.7.4. By End-user
12.7.5. By Country/Sub-region
13. Asia Pacific Continuous Renal Replacement Therapy Market Analysis and Forecast
13.1. Introduction
13.1.1. Key Findings
13.2. Market Value Forecast, by Mode, 2017–2031
13.2.1. Slow Continuous Ultrafiltration (SCUF)
13.2.2. Continuous Venovenous Hemofiltration (CVVHF)
13.2.3. Continuous Venovenous Hemodialysis (CVVHD)
13.2.4. Continuous Venovenous Hemodiafiltration (CVVHDF)
13.3. Market Value Forecast, by Product, 2017–2031
13.3.1. Dialysate & Replacement Fluids
13.3.2. Disposables
13.3.2.1. Bloodline Sets
13.3.2.2. Hemofilters
13.3.2.3. Other Disposables
13.3.3. Systems
13.4. Market Value Forecast, by Therapy, 2017–2031
13.4.1. Renal
13.4.2. Non-renal
13.4.3. Combination
13.5. Market Value Forecast, by End-user, 2017–2031
13.5.1. Hospitals
13.5.2. Clinics
13.5.3. Others
13.6. Market Value Forecast, by Country/Sub-region, 2017–2031
13.6.1. China
13.6.2. Japan
13.6.3. India
13.6.4. Australia & New Zealand
13.6.5. Rest of Asia Pacific
13.7. Market Attractiveness Analysis
13.7.1. By Mode
13.7.2. By Product
13.7.3. By Therapy
13.7.4. By End-user
13.7.5. By Country/Sub-region
14. Latin America Continuous Renal Replacement Therapy Market Analysis and Forecast
14.1. Introduction
14.1.1. Key Findings
14.2. Market Value Forecast, by Mode, 2017–2031
14.2.1. Slow Continuous Ultrafiltration (SCUF)
14.2.2. Continuous Venovenous Hemofiltration (CVVHF)
14.2.3. Continuous Venovenous Hemodialysis (CVVHD)
14.2.4. Continuous Venovenous Hemodiafiltration (CVVHDF)
14.3. Market Value Forecast, by Product, 2017–2031
14.3.1. Dialysate & Replacement Fluids
14.3.2. Disposables
14.3.2.1. Bloodline Sets
14.3.2.2. Hemofilters
14.3.2.3. Other Disposables
14.3.3. Systems
14.4. Market Value Forecast, by Therapy, 2017–2031
14.4.1. Renal
14.4.2. Non-renal
14.4.3. Combination
14.5. Market Value Forecast, by End-user, 2017–2031
14.5.1. Hospitals
14.5.2. Clinics
14.5.3. Others
14.6. Market Value Forecast, by Country/Sub-region, 2017–2031
14.6.1. Brazil
14.6.2. Mexico
14.6.3. Rest of Latin America
14.7. Market Attractiveness Analysis
14.7.1. By Mode
14.7.2. By Product
14.7.3. By Therapy
14.7.4. By End-user
14.7.5. By Country/Sub-region
15. Middle East & Africa Continuous Renal Replacement Therapy Market Analysis and Forecast
15.1. Introduction
15.1.1. Key Findings
15.2. Market Value Forecast, by Mode, 2017–2031
15.2.1. Slow Continuous Ultrafiltration (SCUF)
15.2.2. Continuous Venovenous Hemofiltration (CVVHF)
15.2.3. Continuous Venovenous Hemodialysis (CVVHD)
15.2.4. Continuous Venovenous Hemodiafiltration (CVVHDF)
15.3. Market Value Forecast, by Product, 2017–2031
15.3.1. Dialysate & Replacement Fluids
15.3.2. Disposables
15.3.2.1. Bloodline Sets
15.3.2.2. Hemofilters
15.3.2.3. Other Disposables
15.3.3. Systems
15.4. Market Value Forecast, by Therapy, 2017–2031
15.4.1. Renal
15.4.2. Non-renal
15.4.3. Combination
15.5. Market Value Forecast, by End-user, 2017–2031
15.5.1. Hospitals
15.5.2. Clinics
15.5.3. Others
15.6. Market Value Forecast, by Country/Sub-region, 2017–2031
15.6.1. GCC Countries
15.6.2. South Africa
15.6.3. Rest of Middle East & Africa
15.7. Market Attractiveness Analysis
15.7.1. By Mode
15.7.2. By Product
15.7.3. By Therapy
15.7.4. By End-user
15.7.5. By Country/Sub-region
16. Competition Landscape
16.1. Market Player – Competition Matrix (By Tier and Size of companies)
16.2. Market Position By Company (2021)
16.3. Company Profiles
16.3.1. Baxter International, Inc.
16.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.1.2. Product Portfolio
16.3.1.3. SWOT Analysis
16.3.1.4. Strategic Overview
16.3.2. Nipro Corporation
16.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.2.2. Product Portfolio
16.3.2.3. SWOT Analysis
16.3.2.4. Strategic Overview
16.3.3. Asahi Kasei Corporation
16.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.3.2. Product Portfolio
16.3.3.3. SWOT Analysis
16.3.3.4. Strategic Overview
16.3.4. B. Braun Melsungen AG
16.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.4.2. Product Portfolio
16.3.4.3. SWOT Analysis
16.3.4.4. Strategic Overview
16.3.5. Medica SPA
16.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.5.2. Product Portfolio
16.3.5.3. SWOT Analysis
16.3.5.4. Strategic Overview
16.3.6. INFOMED SA
16.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.6.2. Product Portfolio
16.3.6.3. SWOT Analysis
16.3.6.4. Strategic Overview
16.3.7. Medtronic
16.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.7.2. Product Portfolio
16.3.7.3. SWOT Analysis
16.3.7.4. Strategic Overview
16.3.8. Toray Medical Company Limited (Toray Industries, Inc.)
16.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.8.2. Product Portfolio
16.3.8.3. SWOT Analysis
16.3.8.4. Strategic Overview
List of Tables
Table 01: Opportunity Map, by Mode, 2021
Table 02: Market Opportunity Map, by Product Type, 2021
Table 03: Opportunity Map, by Therapy, 2021
Table 04: Opportunity Map, by End-user, 2021
Table 05: Global Continuous Renal Replacement Therapy Market Revenue (US$ Mn) Forecast, by Mode, 2017–2031
Table 06: Global Continuous Renal Replacement Therapy Market Revenue (US$ Mn) Forecast, by Product, 2017–2031
Table 07: Global Continuous Renal Replacement Therapy Market Revenue (US$ Mn) Forecast, by Disposables, 2017–2031
Table 08: Global Continuous Renal Replacement Therapy Market Revenue (US$ Mn) Forecast, by Therapy, 2017–2031
Table 09: Global Continuous Renal Replacement Therapy Market Revenue (US$ Mn) Forecast, by End-user, 2017–2031
Table 10: Global Continuous Renal Replacement Therapy Market Revenue (US$ Mn) Forecast, by Region, 2017–2031
Table 11: North America Continuous Renal Replacement Therapy Market Revenue (US$ Mn) Forecast, by Mode, 2017–2031
Table 12: North America Continuous Renal Replacement Therapy Market Revenue (US$ Mn) Forecast, by Product, 2017–2031
Table 13: North America Continuous Renal Replacement Therapy Market Revenue (US$ Mn) Forecast, by Disposables, 2017–2031
Table 14: North America Continuous Renal Replacement Therapy Market Revenue (US$ Mn) Forecast, by Therapy, 2017–2031
Table 15: North America Continuous Renal Replacement Therapy Market Revenue (US$ Mn) Forecast, by End-user, 2017–2031
Table 16: North America Continuous Renal Replacement Therapy Market Revenue (US$ Mn) Forecast, by Country, 2017–2031
Table 17: Europe Continuous Renal Replacement Therapy Market Revenue (US$ Mn) Forecast, by Mode, 2017–2031
Table 18: Europe Continuous Renal Replacement Therapy Market Revenue (US$ Mn) Forecast, by Product, 2017–2031
Table 19: Europe Continuous Renal Replacement Therapy Market Revenue (US$ Mn) Forecast, by Disposables, 2017–2031
Table 20: Europe Continuous Renal Replacement Therapy Market Revenue (US$ Mn) Forecast, by Therapy, 2017–2031
Table 21: Europe Continuous Renal Replacement Therapy Market Revenue (US$ Mn) Forecast, by End-user, 2017–2031
Table 22: Europe Continuous Renal Replacement Therapy Market Revenue (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
Table 23: Asia Pacific Continuous Renal Replacement Therapy Market Revenue (US$ Mn) Forecast, by Mode, 2017–2031
Table 24: Asia Pacific Continuous Renal Replacement Therapy Market Revenue (US$ Mn) Forecast, by Product, 2017–2031
Table 25: Asia Pacific Continuous Renal Replacement Therapy Market Revenue (US$ Mn) Forecast, by Disposables, 2017–2031
Table 26: Asia Pacific Continuous Renal Replacement Therapy Market Revenue (US$ Mn) Forecast, by Therapy, 2017–2031
Table 27: Asia Pacific Continuous Renal Replacement Therapy Market Revenue (US$ Mn) Forecast, by End-user, 2017–2031
Table 28: Asia Pacific Continuous Renal Replacement Therapy Market Revenue (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
Table 29: Latin America Continuous Renal Replacement Therapy Market Revenue (US$ Mn) Forecast, by Mode, 2017–2031
Table 30: Latin America Continuous Renal Replacement Therapy Market Revenue (US$ Mn) Forecast, by Product, 2017–2031
Table 31: Latin America Continuous Renal Replacement Therapy Market Revenue (US$ Mn) Forecast, by Disposables, 2017–2031
Table 32: Latin America Continuous Renal Replacement Therapy Market Revenue (US$ Mn) Forecast, by Therapy, 2017–2031
Table 33: Latin America Continuous Renal Replacement Therapy Market Revenue (US$ Mn) Forecast, by End-user, 2017–2031
Table 34: Latin America Continuous Renal Replacement Therapy Market Revenue (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
Table 35: Middle East & Africa Continuous Renal Replacement Therapy Market Revenue (US$ Mn) Forecast, by Mode, 2017–2031
Table 36: Middle East & Africa Continuous Renal Replacement Therapy Market Revenue (US$ Mn) Forecast, by Product, 2017–2031
Table 37: Middle East & Africa Continuous Renal Replacement Therapy Market Revenue (US$ Mn) Forecast, by Disposables, 2017–2031
Table 38: Middle East & Africa Continuous Renal Replacement Therapy Market Revenue (US$ Mn) Forecast, by Therapy, 2017–2031
Table 39: Middle East & Africa Continuous Renal Replacement Therapy Market Revenue (US$ Mn) Forecast, by End-user, 2017–2031
Table 40: Middle East & Africa Continuous Renal Replacement Therapy Market Revenue (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
List of Figures
Figure 01: Global Continuous Renal Replacement Therapy Market Revenue (US$ Mn) and End-user, by Region, 2021 and 2031
Figure 02: Global Continuous Renal Replacement Therapy Market Share Analysis, by Region, 2021
Figure 03: Global Continuous Renal Replacement Therapy Market Revenue (US$ Mn) Forecast, 2017–2031
Figure 04: Global Continuous Renal Replacement Therapy Market Revenue Share, by Mode, 2021
Figure 05: Global Continuous Renal Replacement Therapy Market Revenue Share, by Product, 2021
Figure 06: Global Continuous Renal Replacement Therapy Market Revenue Share, by Therapy, 2021
Figure 07: Global Continuous Renal Replacement Therapy Market Revenue Share, by End-user, 2021
Figure 08: Global Continuous Renal Replacement Therapy Market Revenue Share, by Region, 2021
Figure 09: Global Continuous Renal Replacement Therapy Market Revenue Share, by Mode, 2021 and 2031
Figure 10: Global Continuous Renal Replacement Therapy Market Attractiveness Analysis, by Mode, 2022–2031
Figure 11: Global Continuous Renal Replacement Therapy Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by SCUF, 2017–2031
Figure 12: Global Continuous Renal Replacement Therapy Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by CVVH, 2017–2031
Figure 13: Global Continuous Renal Replacement Therapy Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by CVVHD, 2017–2031
Figure 14: Global Continuous Renal Replacement Therapy Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by CVVHDF, 2017–2031
Figure 15: Global Continuous Renal Replacement Therapy Market Revenue Share Analysis, by Product, 2021 and 2031
Figure 16: Global Continuous Renal Replacement Therapy Market Attractiveness Analysis, by Product, 2022–2031
Figure 17 A: Global Continuous Renal Replacement Therapy Market Revenue (US$ Mn) Forecast, by Dialysate & Replacement Fluids, 2017–2031
Figure 17 B: Global Continuous Renal Replacement Therapy Market Revenue (US$ Mn) Forecast, by Disposables, 2017–2031
Figure 18: Global Continuous Renal Replacement Therapy Market Revenue (US$ Mn) Forecast, by Systems, 2017–2031
Figure 19: Global Continuous Renal Replacement Therapy Market Revenue Share Analysis, by Therapy, 2021 and 2031
Figure 20: Global Continuous Renal Replacement Therapy Market Attractiveness Analysis, by Therapy, 2022–2031
Figure 21: Global Continuous Renal Replacement Therapy Market Revenue (US$ Mn) Forecast, by Renal, 2022–2031
Figure 22: Global Continuous Renal Replacement Therapy Market Revenue (US$ Mn) ) Forecast , by Non-renal, 2022–2031
Figure 23: Global Continuous Renal Replacement Therapy Market Revenue (US$ Mn) Forecast, by Combination, 2022–2031
Figure 24: Global Continuous Renal Replacement Therapy Market Revenue Share, by End-user, 2021 and 2031
Figure 25: Global Continuous Renal Replacement Therapy Market Attractiveness Analysis, by End-user, 2022–2031
Figure 26: Global Continuous Renal Replacement Therapy Market Revenue (US$ Mn) ) Forecast and Y-o-Y Growth (%), by Hospitals, 2022–2031
Figure 27: Global Continuous Renal Replacement Therapy Market Revenue (US$ Mn) ) Forecast and Y-o-Y Growth (%), by Clinics, 2022–2031
Figure 28: Global Continuous Renal Replacement Therapy Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%), by Others, 2022–2031
Figure 29: Global Continuous Renal Replacement Therapy Market Revenue Share, by Region, 2021 and 2031
Figure 30: Global Continuous Renal Replacement Therapy Market Attractiveness Analysis, by Region, 2022–2031
Figure 31: North America Continuous Renal Replacement Therapy Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2022–2031
Figure 32: North America Continuous Renal Replacement Therapy Market Revenue Share, by Mode, 2021 and 2031
Figure 33: North America Continuous Renal Replacement Therapy Market Attractiveness Analysis, by Mode, 2022–2031
Figure 34: North America Continuous Renal Replacement Therapy Market Revenue Share, by Product, 2021 and 2031
Figure 35: North America Continuous Renal Replacement Therapy Market Attractiveness Analysis, by Product, 2022–2031
Figure 36: North America Continuous Renal Replacement Therapy Market Revenue Share, by Therapy, 2021 and 2031
Figure 37: North America Continuous Renal Replacement Therapy Market Attractiveness Analysis, by Therapy, 2022–2031
Figure 38: North America Continuous Renal Replacement Therapy Market Revenue Share, by End-user, 2021 and 2031
Figure 39: North America Continuous Renal Replacement Therapy Market Attractiveness Analysis, by End-user, 2022–2031
Figure 40: North America Continuous Renal Replacement Therapy Market Revenue Share, by Country, 2021 and 2031
Figure 41: North America Continuous Renal Replacement Therapy Market Attractiveness Analysis, by Country, 2022–2031
Figure 42: Europe Continuous Renal Replacement Therapy Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2022–2031
Figure 43: Europe Continuous Renal Replacement Therapy Market Revenue Share, by Mode, 2021 and 2031
Figure 44: Europe Continuous Renal Replacement Therapy Market Attractiveness Analysis, by Mode, 2022–2031
Figure 45: Europe Continuous Renal Replacement Therapy Market Revenue Share, by Product, 2021 and 2031
Figure 46: Europe Continuous Renal Replacement Therapy Market Attractiveness Analysis, by Product, 2022–2031
Figure 47: Europe Continuous Renal Replacement Therapy Market Revenue Share, by Therapy, 2021 and 2031
Figure 48: Europe Continuous Renal Replacement Therapy Market Attractiveness Analysis, by Therapy, 2022–2031
Figure 49: Europe Continuous Renal Replacement Therapy Market Revenue Share, by End-user, 2021 and 2031
Figure 50: Europe Continuous Renal Replacement Therapy Market Attractiveness Analysis, by End-user, 2022–2031
Figure 51: Europe Continuous Renal Replacement Therapy Market Revenue Share, by Country/Sub-region, 2021 and 2031
Figure 52: Europe Continuous Renal Replacement Therapy Market Attractiveness Analysis, by Country/Sub-region, 2022–2031
Figure 53: Asia Pacific Continuous Renal Replacement Therapy Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2022–2031
Figure 54: Asia Pacific Continuous Renal Replacement Therapy Market Revenue Share, by Mode, 2021 and 2031
Figure 55: Asia Pacific Continuous Renal Replacement Therapy Market Attractiveness Analysis, by Mode, 2022–2031
Figure 56: Asia Pacific Continuous Renal Replacement Therapy Market Revenue Share, by Product, 2021 and 2031
Figure 57: Asia Pacific Continuous Renal Replacement Therapy Market Attractiveness Analysis, by Product, 2022–2031
Figure 58: Asia Pacific Continuous Renal Replacement Therapy Market Revenue Share, by Therapy, 2021 and 2031
Figure 59: Asia Pacific Continuous Renal Replacement Therapy Market Attractiveness Analysis, by Therapy, 2022–2031
Figure 60: Asia Pacific Continuous Renal Replacement Therapy Market Revenue Share, by End-user, 2021 and 2031
Figure 61: Asia Pacific Continuous Renal Replacement Therapy Market Attractiveness Analysis, by End-user, 2022–2031
Figure 62: Asia Pacific Continuous Renal Replacement Therapy Market Revenue Share, by Country/Sub-region, 2021 and 2031
Figure 63: Asia Pacific Continuous Renal Replacement Therapy Market Attractiveness Analysis, by Country/Sub-region, 2022–2031
Figure 64: Latin America Continuous Renal Replacement Therapy Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2022–2031
Figure 65: Latin America Continuous Renal Replacement Therapy Market Revenue Share, by Mode, 2021 and 2031
Figure 66: Latin America Continuous Renal Replacement Therapy Market Attractiveness Analysis, by Mode, 2022–2031
Figure 67: Latin America Continuous Renal Replacement Therapy Market Revenue Share, by Product, 2021 and 2031
Figure 68: Latin America Continuous Renal Replacement Therapy Market Attractiveness Analysis, by Product, 2022–2031
Figure 69: Latin America Continuous Renal Replacement Therapy Market Revenue Share, by Therapy, 2021 and 2031
Figure 70: Latin America Continuous Renal Replacement Therapy Market Attractiveness Analysis, by Therapy, 2022–2031
Figure 71: Latin America Continuous Renal Replacement Therapy Market Revenue Share, by End-user, 2021 and 2031
Figure 72: Latin America Continuous Renal Replacement Therapy Market Attractiveness Analysis, by End-user, 2022–2031
Figure 73: Latin America Continuous Renal Replacement Therapy Market Revenue Share, by Country/Sub-region, 2021 and 2031
Figure 74: Latin America Continuous Renal Replacement Therapy Market Attractiveness Analysis, by Country/Sub-region, 2022–2031
Figure 75: Middle East & Africa Continuous Renal Replacement Therapy Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2022–2031
Figure 76: Middle East & Africa Continuous Renal Replacement Therapy Market Revenue Share, by Mode, 2021 and 2031
Figure 77: Middle East & Africa Continuous Renal Replacement Therapy Market Attractiveness Analysis, by Mode, 2022–2031
Figure 78: Middle East & Africa Continuous Renal Replacement Therapy Market Revenue Share, by Product, 2021 and 2031
Figure 79: Middle East & Africa Continuous Renal Replacement Therapy Market Attractiveness Analysis, by Product, 2022–2031
Figure 80: Middle East & Africa Continuous Renal Replacement Therapy Market Revenue Share, by Therapy, 2021 and 2031
Figure 81: Middle East & Africa Continuous Renal Replacement Therapy Market Attractiveness Analysis, by Therapy, 2022–2031
Figure 82: Middle East & Africa Continuous Renal Replacement Therapy Market Revenue Share, by End-user, 2021 and 2031
Figure 83: Middle East & Africa Continuous Renal Replacement Therapy Market Attractiveness Analysis, by End-user, 2022–2031
Figure 84: Middle East & Africa Continuous Renal Replacement Therapy Market Revenue Share, by Country/Sub-region, 2021 and 2031
Figure 85: Middle East & Africa Continuous Renal Replacement Therapy Market Attractiveness Analysis, by Country/Sub-region, 2022-2031
Copyright © Transparency Market Research, Inc. All Rights reserved
Trust Online
Continuous Renal Replacement Therapy Market
